⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12308060 | 0.70 | CRBN (0.32) | — | |
| SCHEMBL13236545 | 0.70 | LMNA (0.34) | — | |
| SCHEMBL9509 | 0.67 | — | — | |
| SCHEMBL2784389 | 0.67 | — | — | |
| SCHEMBL13546953 | 0.67 | — | — | |
| SCHEMBL25460677 | 0.67 | — | — | |
| SCHEMBL13028695 | 0.67 | CCR2 (0.38) | — | |
| SCHEMBL13036916 | 0.63 | BRD4 (0.33) | — | |
| SCHEMBL19223482 | 0.63 | PRCP (0.56) | — | |
| SCHEMBL22928100 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |